INTELLIA THERAPEUTICS INC's ticker is NTLA and the CUSIP is 45826J105. A total of 245 filers reported holding INTELLIA THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 4.51 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $29,102,638 | -22.3% | 920,387 | +0.2% | 0.01% | -14.3% |
| Q2 2023 | $37,457,327 | +32.0% | 918,522 | +20.6% | 0.01% | +16.7% |
| Q1 2023 | $28,380,732 | +5.7% | 761,490 | -1.1% | 0.01% | 0.0% |
| Q4 2022 | $26,860,415 | -31.9% | 769,860 | +9.2% | 0.01% | -33.3% |
| Q3 2022 | $39,439,000 | +8.2% | 704,774 | +0.1% | 0.01% | +12.5% |
| Q2 2022 | $36,442,000 | -27.3% | 704,057 | +2.1% | 0.01% | -11.1% |
| Q1 2022 | $50,114,000 | -42.6% | 689,611 | -6.5% | 0.01% | -35.7% |
| Q4 2021 | $87,239,000 | -12.6% | 737,803 | -0.8% | 0.01% | -22.2% |
| Q3 2021 | $99,770,000 | -12.9% | 743,718 | +5.1% | 0.02% | -10.0% |
| Q2 2021 | $114,518,000 | +121.3% | 707,297 | +9.7% | 0.02% | +100.0% |
| Q1 2021 | $51,750,000 | +48.2% | 644,821 | +0.5% | 0.01% | +42.9% |
| Q4 2020 | $34,919,000 | +169.6% | 641,907 | -1.5% | 0.01% | +133.3% |
| Q3 2020 | $12,950,000 | +30.6% | 651,407 | +38.1% | 0.00% | +50.0% |
| Q2 2020 | $9,914,000 | +58.6% | 471,632 | -7.7% | 0.00% | 0.0% |
| Q1 2020 | $6,249,000 | -15.2% | 510,891 | +1.7% | 0.00% | 0.0% |
| Q4 2019 | $7,370,000 | +12.4% | 502,410 | +2.3% | 0.00% | 0.0% |
| Q3 2019 | $6,559,000 | -1.8% | 491,294 | +20.4% | 0.00% | 0.0% |
| Q2 2019 | $6,678,000 | -0.8% | 407,948 | +3.5% | 0.00% | 0.0% |
| Q1 2019 | $6,733,000 | +26.5% | 394,211 | +1.1% | 0.00% | +100.0% |
| Q4 2018 | $5,322,000 | -52.8% | 389,930 | -1.0% | 0.00% | -66.7% |
| Q3 2018 | $11,269,000 | +13.1% | 393,769 | +8.1% | 0.00% | 0.0% |
| Q2 2018 | $9,963,000 | +155.9% | 364,171 | +97.3% | 0.00% | +200.0% |
| Q1 2018 | $3,894,000 | +10.8% | 184,618 | +1.0% | 0.00% | 0.0% |
| Q4 2017 | $3,514,000 | -7.1% | 182,836 | +20.2% | 0.00% | 0.0% |
| Q3 2017 | $3,781,000 | +546.3% | 152,159 | +315.8% | 0.00% | – |
| Q2 2017 | $585,000 | -45.6% | 36,596 | -52.0% | 0.00% | – |
| Q1 2017 | $1,075,000 | +5.2% | 76,295 | -2.1% | 0.00% | – |
| Q4 2016 | $1,022,000 | -20.3% | 77,959 | +3.4% | 0.00% | – |
| Q3 2016 | $1,283,000 | -20.6% | 75,396 | -0.4% | 0.00% | -100.0% |
| Q2 2016 | $1,615,000 | – | 75,683 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Discovery Value Fund | 561,561 | $17,756,559 | 9.73% |
| MPM BioImpact LLC | 544,639 | $17,221,485 | 4.60% |
| Casdin Capital, LLC | 1,178,075 | $37,250,732 | 4.12% |
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 1,145,091 | $36,207,777 | 3.72% |
| Atlas Venture Associates IX, LLC | 10,000 | $316,200 | 2.69% |
| Deep Track Capital, LP | 2,000,000 | $63,240,000 | 2.44% |
| ARK Investment Management | 9,948,629 | $314,575,638 | 2.41% |
| Merlin Capital, Inc | 18,526 | $585,792 | 2.19% |
| Orchard Capital Management, LLC | 159,155 | $5,032,481 | 1.86% |
| TANG CAPITAL MANAGEMENT LLC | 397,600 | $12,572,112 | 1.77% |